Ameriprise
RNAM

Ameriprise’s Avidity Biosciences RNAM Stock Holding History

Ameriprise’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,164
Closed -$950K – 4199
2025
Q4 		$950K Sell
13,164
-620
-4% -$40K ﹤0.01% 3368
2025
Q3 		$601K Buy
13,784
+821
+6% +$33.2K ﹤0.01% 3565
2025
Q2 		$368K Sell
12,963
-14,675
-53% -$437K ﹤0.01% 3633
2025
Q1 		$816K Buy
27,638
+194
+0.7% +$6.04K ﹤0.01% 3289
2024
Q4 		$798K Buy
27,444
+14,129
+106% +$590K ﹤0.01% 3334
2024
Q3 		$612K Sell
13,315
-26,729
-67% -$1.16M ﹤0.01% 3415
2024
Q2 		$1.64M Buy
40,044
+23,199
+138% +$666K ﹤0.01% 2950
2024
Q1 		$430K Buy
16,845
+5,495
+48% +$86.1K ﹤0.01% 3467
2023
Q4 		$103K Buy
+11,350
New +$75.9K ﹤0.01% 3811
2021
Q4 		– Sell
-8,360
Closed -$206K – 4038
2021
Q3 		$206K Buy
+8,360
New +$182K ﹤0.01% 3697

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Ameriprise's RNAM Position: Q1 2026 in Review

Ameriprise sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 13,164 shares — an estimated $950K sold.

Ameriprise first reported a position in RNAM in Q3 2021 and held it in 10 quarters. The position peaked at $1.64M in Q2 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Ameriprise reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 13,164 Avidity Biosciences shares in Q1 2026, an estimated $950K.
  • Ameriprise first reported a position in Avidity Biosciences in Q3 2021 and held it in 10 quarters.
  • Ameriprise's Avidity Biosciences position peaked at $1.64M in Q2 2024.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.